Simonds William F, Robbins Christiane M, Agarwal Sunita K, Hendy Geoffrey N, Carpten John D, Marx Stephen J
Metabolic Diseases Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA.
J Clin Endocrinol Metab. 2004 Jan;89(1):96-102. doi: 10.1210/jc.2003-030675.
Familial isolated hyperparathyroidism (FIHP) can result occasionally from the incomplete expression of a syndromic form of familial hyperparathyroidism (HPT), specifically multiple endocrine neoplasia type 1 (MEN1), familial hypocalciuric hypercalcemia, or the hyperparathyroidism-jaw tumor syndrome (HPT-JT). The cause of FIHP has not been identified in the majority of families. We investigated 32 families with FIHP to determine the frequency of occult mutation in HRPT2, the gene causing HPT-JT. All families had negative clinical testing for MEN1, hypocalciuric hypercalcemia, and HPT-JT and negative mutational screening of MEN1 and CASR, the gene for the calcium-sensing receptor. Thus, an extended effort was made to exclude each of the principal syndromic causes of FIHP. The families were characterized by young probands (42 +/- 3 yr) and occasionally unusual parathyroid histology, including four families with one case of parathyroid cancer. We had speculated that there was a high frequency of occult mutation in HRPT2 among such carefully screened kindreds. This hypothesis became testable with the recent identification of that gene. Among the 32 FIHP families, only a single one was found to have a mutation in HRPT2 (679insAG); this mutation predicts premature truncation of its gene product, parafibromin, and thus its presumed inactivation. Even accounting for families with one of the three occult syndromes and false negative biochemical or DNA testing, these results indicate that an unexpectedly large fraction of FIHP has currently unrecognized causes.
家族性孤立性甲状旁腺功能亢进症(FIHP)偶尔可由家族性甲状旁腺功能亢进症(HPT)综合征形式的不完全表达引起,特别是多发性内分泌腺瘤1型(MEN1)、家族性低钙血症性高钙血症或甲状旁腺功能亢进-颌骨肿瘤综合征(HPT-JT)。在大多数家族中,FIHP的病因尚未明确。我们对32个FIHP家族进行了研究,以确定导致HPT-JT的HRPT2基因隐匿性突变的频率。所有家族的MEN1、低钙血症性高钙血症和HPT-JT临床检测均为阴性,MEN1和钙敏感受体基因CASR的突变筛查也为阴性。因此,我们进行了进一步的努力以排除FIHP的每一种主要综合征病因。这些家族的特点是先证者年轻(42±3岁),甲状旁腺组织学偶尔异常,包括4个家族中有1例甲状旁腺癌。我们曾推测,在经过如此仔细筛查的家族中,HRPT2基因隐匿性突变的频率较高。随着该基因的最近发现,这一假设变得可以检验。在32个FIHP家族中,仅发现1个家族的HRPT2基因存在突变(679insAG);该突变预测其基因产物 parafibromin会提前截断,从而可能使其失活。即使将患有三种隐匿综合征之一的家族以及生化或DNA检测假阴性的家族考虑在内,这些结果表明,目前FIHP有很大一部分病因尚未被认识。